Abstract
A new radiopharmaceutical for liver scintigraphy has been prepared by reacting 169YbOCl with Na phytate under conditions which yield a labelling efficiency of more than 99% over a wide pH range. In rabbits the resultant colloidal preparation shows a rapid elimination from the blood and high initial uptake in liver. Subsequently about 90% of the liver activity is lost within 3 days, the remainder being eliminated more slowly. The radiopharmaceutical is non-toxic and has a shelf-life of about 3 months. Scintigrams obtained in patients with hepatomegaly suggest that this new agent gives better visualization of space occupying lesions of the liver than 99 m TcSn colloid. The radiation dose to the patient from this agent is low and comparable with that from other radiopharmaceuticals used for liver scintigraphy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: The International Journal Of Applied Radiation And Isotopes
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.